



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** September 8, 2006

**To:** Primary Clinical Research Associates

**From:** Janis Wobschall  
Protocol Development Coordinator

**Re:** N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

Attached, please find a revised status change notice dated August 4, 2006 which now correctly reflects that this study is **temporarily** closed rather than permanently closed.

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg  
Enclosure